Page 377 - IJB-10-6
P. 377
International Journal of Bioprinting 3D-printed NAFLD model
Figure 5. Study of the bioprinted non-alcoholic fatty liver disease (NAFLD) model for NAFLD prevention and reversal. (A–D) Investigation on NAFLD
prevention. (A) Experimental procedure for drug prevention. (B) Analysis of cell viability under different drug concentrations. (C) Analysis of lipid
accumulation under different drug concentrations. (D) Fluorescence images of lipid accumulation under different drug concentrations. (E–H) Investigation
on NAFLD reversibility. (E) Experimental procedure for drug reversibility. (F) Analysis of cell viability under different drug concentrations. (G) Analysis
of lipid accumulation under different drug concentrations. (H) Fluorescence images of lipid accumulation under different drug concentrations. Scale bar:
200 µm. ***p < 0.001. Abbreviations: FFAs: Free fatty acids; ELA: Elafibranor; N.S.: No significant difference.
Volume 10 Issue 6 (2024) 369 doi: 10.36922/ijb.4312
